nā lāʻau lapaʻau hou ʻole liʻiliʻi cell lung cancer

ʻO ka maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi (NSCLC) ke kumu nui o ka make pili i ka maʻi kanesa ma ka honua holoʻokoʻa. ʻO ka mea pōmaikaʻi, ke kū mai nei nā holomua nui i nā koho lapaʻau, e hāʻawi ana i ka manaʻolana hou no nā hopena maikaʻi a me ka maikaʻi o ke ola. ʻIke kēia ʻatikala i nā mea hou loa nā lāʻau lapaʻau hou ʻole liʻiliʻi cell lung cancer, me nā lāʻau lapaʻau i hoʻopaʻa ʻia, immunotherapies, hui pū ʻana o ka chemotherapy, a me nā hoʻāʻo hoʻokolohua hou. Hoʻopili ia i kekahi mau subtypes, me ka adenocarcinoma, squamous cell carcinoma, a me ka carcinoma cell nui. ʻO ka pae o ka NSCLC ma ka maʻi maʻi e pili nui i nā koho lapaʻau a me ka wānana. Hiki ke mālama ʻia ka NSCLC mua me ka ʻokiʻoki, ʻoiai ʻo nā pae kiʻekiʻe e koi pinepine i ka hui pū ʻana o nā lāʻau lapaʻau. ʻOi aku ka maikaʻi o kēia mau lāʻau lapaʻau a ʻoi aku ka liʻiliʻi o nā hopena ʻaoʻao ma mua o ka chemotherapy maʻamau. ʻO nā pahuhopu maʻamau i ka NSCLC e komo pū me EGFR, ALK, ROS1, BRAF, a me MET.EGFR InhibitorsEpidermal growth factor receptor (EGFR) he protein e kōkua ana i nā cell e ulu a māhele. ʻO kekahi mau maʻi maʻi NSCLC he mau hoʻololi i ka gene EGFR, e alakaʻi ana i ka ulu ʻana o ke kelepona ʻole. ʻO nā mea hoʻopaneʻe EGFR, e like me gefitinib, erlotinib, afatinib, a me osimertinib, e ālai i ka hana o EGFR, e hoʻolohi a hoʻōki i ka ulu ʻana o ka maʻi tumora.Nā pōmaikaʻi: Hoʻohana pinepine i nā mea maʻi me nā hoʻololi EGFR, e alakaʻi ana i ka hoʻomaikaʻi ʻana i ke ola a me ka maikaʻi o ke ola.Nā hopena ʻaoʻao: ʻO ka ʻili o ka ʻili, ka maʻi ʻeha, ka luhi. ʻO Osimertinib ka mea maʻamau i ka lāʻau lapaʻau mua no ka EGFR-mutated NSCLC, e hōʻike ana i ka ʻoi aku ka maikaʻi ma mua o ka hanauna mua o ka EGFR inhibitors. Hiki iā ʻoe ke aʻo hou aʻe e pili ana i ka EGFR inhibitors mai ka Paena pūnaewele ʻo American Cancer Society.ALK InhibitorsAnaplastic lymphoma kinase (ALK) kekahi pūmua i hiki ke hoʻololi ʻia ma NSCLC. ʻO nā mea hoʻopaneʻe ALK, e like me crizotinib, ceritinib, alectinib, brigatinib, a me lorlatinib, e kuhikuhi i ka protein ALK, e kāohi ana i kāna hana a pale i ka ulu ʻana o ka tumor.Nā pōmaikaʻi: Pono i nā poʻe maʻi me nā hoʻonohonoho hou ʻana o ALK, e hopena i ka hoʻomaikaʻi ʻana i ke ola a me ka hōʻemi ʻana i ka piʻi ʻana o ka maʻi.Nā hopena ʻaoʻao: ʻO nā loli o ka hihiʻo, ka nausea, ka luaʻi, ka maʻi paʻi, ka luhi. ʻO Alectinib a me Lorlatinib ka mea makemake pinepine i nā lāʻau lapaʻau mua ma muli o ko lākou maikaʻi maikaʻi a me ka hiki ke komo i ka pale koko-lolo, he mea nui ia no nā maʻi me nā metastases lolo. ʻImi ʻImi maʻi maʻi UK hāʻawi i ka ʻike hou aku. ʻO ka ROS1 InhibitorsROS1 he kinase tyrosine kinase e hiki ke hoʻoulu i ka ulu ʻana o ka maʻi kanesa. Hoʻohana ʻia nā mea hoʻopale ROS1, e like me crizotinib a me entrectinib, e mālama i ka NSCLC me nā fusions ROS1.Nā pōmaikaʻi: ʻO ka emi ʻana o ka tumo nui a me ka lōʻihi o ke ola ʻana i nā maʻi me ka ROS1-positive NSCLC.Nā hopena ʻaoʻao: E like me ka ALK inhibitors. Ua hōʻike ʻo Entrectinib i ka ʻōlelo hoʻohiki ma muli o kona hiki ke hele i ka pale koko-lolo, e hana pono ai no ka mālama ʻana i nā metastases lolo. E nānā i ka Paena pūnaewele ʻo European Medicines Agency no ka ʻike kikoʻī. Hoʻohana ka Immunotherapy no NSCLCImmunotherapy i ka mana o ke kino ponoʻī o ke kino e hakakā i ka maʻi kanesa. He ʻano ʻano immunotherapy ka pale ʻana i nā protein e pale ai i ka ʻōnaehana pale mai ka hoʻouka ʻana i nā cell cancer. PD-1 / PD-L1 inhibitors, e like me pembrolizumab, nivolumab, atezolizumab, a me durvalumab, e ālai i kēia mau protein, e ʻae i ka ʻōnaehana immune e ʻike a hoʻouka i nā maʻi kanesa.Nā pōmaikaʻi: ʻO nā pane paʻa a me ka hoʻomaikaʻi ʻana i ke ola ma kahi ʻāpana o nā maʻi me NSCLC.Nā hopena ʻaoʻao: ʻO nā hopena pili i ke kino, e like me ka pneumonitis, colitis, a me ka hepatitis. Hoʻohana pinepine ʻia ʻo Pembrolizumab ma ke ʻano he lāʻau lapaʻau mua no nā poʻe maʻi NSCLC me ka hōʻike PD-L1 kiʻekiʻe. Hiki ke loaʻa ka ʻike hou aku ma ka Pūnaewele FDA.CTLA-4 InhibitorsCytotoxic T-lymphocyte-associated protein 4 (CTLA-4) kekahi pūmua e hiki ke hoʻopau i ka ʻōnaehana pale. ʻO Ipilimumab kahi mea hoʻopiʻi CTLA-4 hiki ke hoʻohana ʻia me ka hui pū me ka PD-1 inhibitors e hoʻomaikaʻi i ka pane ʻana i ka pale ʻana i nā maʻi kanesa.Nā pōmaikaʻi: Hiki ke hoʻomaikaʻi i ke ola ke hui pū ʻia me PD-1 inhibitors.Nā hopena ʻaoʻao: ʻOi aku ka nui o nā hopena ʻaoʻao pili i ka immune i hoʻohālikelike ʻia me ka PD-1 inhibitors. ʻO nā lāʻau lapaʻau hou ʻole liʻiliʻi liʻiliʻi i ka maʻi kanesa Hoʻohui pinepine i ka hoʻohui ʻana i ka chemotherapy me ka immunotherapy a i ʻole nā ​​mea lapaʻau i hoʻopaʻa ʻia e hoʻomaikaʻi i ko lākou pono. nā lāʻau lapaʻau hou ʻole liʻiliʻi cell lung cancer. Hoʻohana kēia ala i ka hiki o ka chemotherapy e hoʻopōʻino i nā maʻi maʻi a hoʻokuʻu i nā antigens, e ʻoi aku ka maʻalahi o ka hoʻouka kaua ʻana. Hiki i ka hoʻohui ʻana o ka immunotherapy ke hoʻonui i ka pane ʻana o ka immune, e alakaʻi ana i nā hopena maikaʻi.Nā pōmaikaʻi: Hoʻomaikaʻi i ke ola a me ka pane ʻana i hoʻohālikelike ʻia me ka chemotherapy wale nō.Nā hopena ʻaoʻao: Hoʻonui ʻia ka pilikia o ka chemotherapy a me nā hopena ʻaoʻao pili i ka immune. Hiki i kēia ala ke kōkua i ka pale ʻana i nā mīkini kū'ē a hoʻomaikaʻi i nā hopena lapaʻau.Nā pōmaikaʻi: Hiki ke hoʻihoʻi i ka naʻau i ka lāʻau lapaʻau a hoʻomaikaʻi i ke ola.Nā hopena ʻaoʻao: Hoʻonui ʻia ka pilikia o nā hopena ʻaoʻao mai nā lāʻau lapaʻau ʻelua. Nā Hoʻokolohua Clinical: The Future of NSCLC Treatment ʻO nā hoʻokolohua lapaʻau he noiʻi noiʻi e loiloi ana. nā lāʻau lapaʻau hou ʻole liʻiliʻi cell lung cancer a me nā hoʻolālā. ʻO ka komo ʻana i kahi hoʻokolohua lapaʻau hiki ke hāʻawi i ke komo ʻana i nā lāʻau lapaʻau ʻokiʻoki ʻaʻole i loaʻa ākea. Ua kūpaʻa ʻo Shandong Baofa Cancer Research Institute i ka holomua ʻana i ka noiʻi maʻi maʻi a hāʻawi i nā lawelawe a komo i nā hoʻokolohua lapaʻau e hāʻawi ana i ke komo ʻana i nā lāʻau lapaʻau ʻokiʻoki ʻaʻole i loaʻa ākea. E aʻo hou e pili ana i nā hoʻokolohua lapaʻau ma Shandong Baofa Cancer Research Institute.Emerging Therapies in Clinical TrialsSveral promising nā lāʻau lapaʻau hou ʻole liʻiliʻi cell lung cancer ke loiloi ʻia nei i nā hoʻokolohua lapaʻau, e like me:Nā mea hoʻohui lāʻau antibody (ADCs): Hāʻawi pololei kēia mau lāʻau lapaʻau i ka chemotherapy i nā maʻi maʻi maʻi, e hōʻemi ana i ka pōʻino i nā cell olakino.ʻO nā antibodies Bispecific: Hoʻopaʻa kēia mau antibodies i nā maʻi maʻi ʻelua a me nā cell immune, e hui pū ana iā lākou e hoʻonui i ka pane immune.Nā lāʻau lapaʻau kelepona (e laʻa, CAR-T cell therapy): ʻO kēia mau lāʻau lapaʻau e pili ana i ka hoʻololi ʻana i nā cell immune e hoʻopaʻa a luku i nā maʻi maʻi maʻi. ʻO ka noho ʻana me NSCLC: Nā Punawai a me ke Kākoʻo Hiki ke paʻakikī ka noho ʻana me NSCLC, akā loaʻa nā kumuwaiwai a me nā hui kākoʻo e kōkua i nā poʻe maʻi a me ko lākou ʻohana e hoʻokō i ka maʻi. E noʻonoʻo e ʻimi i nā kumuwaiwai mai nā hui e like me ka ʻAhahui Lung ʻAmelika a i ʻole ka LUNGevity Foundation.Hoʻokuʻu: ʻO kēia ʻatikala no nā kumu ʻike wale nō a ʻaʻole pono e manaʻo ʻia he ʻōlelo aʻoaʻo olakino. E ʻoluʻolu e kamaʻilio me kāu mea mālama ola no nā ʻōlelo aʻoaʻo lapaʻau pilikino.